Isomorphic Labs

Isomorphic Labs is a London-based drug discovery company, spun out of Google DeepMind, that uses AI models building on AlphaFold's protein structure prediction technology to design new medicines.

Isomorphic Labs was founded in 2021 by Demis Hassabis, the co-founder and CEO of Google DeepMind, as a separate but closely affiliated commercial venture specifically focused on applying DeepMind's foundational AI research, particularly its landmark AlphaFold system for predicting protein three-dimensional structures from their amino acid sequences, to the practical challenge of drug discovery, a field where understanding precisely how proteins fold into their functional three-dimensional shapes, and how candidate drug molecules interact with those protein structures, has historically required years of expensive, uncertain laboratory experimentation for each individual drug candidate under development. Isomorphic Labs builds on and extends the AlphaFold technology, along with additional AI models developed specifically for drug discovery applications, to help pharmaceutical researchers more efficiently identify and design promising drug candidate molecules likely to bind effectively to a specific disease-relevant protein target, potentially reducing the enormous cost, time, and high failure rate that has historically characterized traditional drug discovery, where the large majority of drug candidates that enter development ultimately fail, often after years and hundreds of millions of dollars invested in a specific compound, frequently due to properties that better computational prediction earlier in the process might have identified as problematic before extensive laboratory and clinical investment. The company has structured itself as a for-profit drug discovery company distinct from DeepMind's core AI research organization, while maintaining a close technical and organizational relationship given its origins and continued access to DeepMind's underlying AI research advances, and has pursued both its own internal drug discovery programs across multiple disease areas and partnerships with established pharmaceutical companies seeking to apply Isomorphic's AI-driven drug design capabilities to their own drug development pipelines, including a significant multi-year collaboration agreement with Eli Lilly and Novartis. Isomorphic Labs has raised very substantial funding, including from Alphabet itself as well as external investors including Thrive Capital, reaching a valuation exceeding $10 billion.

News

No news available for this company.